Compare NMIH & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMIH | NUVB |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.9B |
| IPO Year | 2013 | N/A |
| Metric | NMIH | NUVB |
|---|---|---|
| Price | $39.89 | $5.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $42.60 | $11.44 |
| AVG Volume (30 Days) | 459.9K | ★ 4.2M |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.06 | N/A |
| EPS | ★ 4.92 | N/A |
| Revenue | ★ $706,440,000.00 | N/A |
| Revenue This Year | N/A | $659.84 |
| Revenue Next Year | $4.34 | $180.43 |
| P/E Ratio | $8.08 | ★ N/A |
| Revenue Growth | ★ 8.52 | N/A |
| 52 Week Low | $32.71 | $1.57 |
| 52 Week High | $43.20 | $9.75 |
| Indicator | NMIH | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 52.75 | 46.80 |
| Support Level | $36.84 | $5.12 |
| Resistance Level | $39.96 | $6.22 |
| Average True Range (ATR) | 1.00 | 0.34 |
| MACD | -0.05 | 0.08 |
| Stochastic Oscillator | 40.87 | 58.93 |
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.